PE20121614A1 - Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 - Google Patents
Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2Info
- Publication number
- PE20121614A1 PE20121614A1 PE2012000827A PE2012000827A PE20121614A1 PE 20121614 A1 PE20121614 A1 PE 20121614A1 PE 2012000827 A PE2012000827 A PE 2012000827A PE 2012000827 A PE2012000827 A PE 2012000827A PE 20121614 A1 PE20121614 A1 PE 20121614A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonists
- carbonyl
- derivatives
- amino
- alkyl
- Prior art date
Links
- 102000004497 CCR2 Receptors Human genes 0.000 title abstract 2
- 108010017312 CCR2 Receptors Proteins 0.000 title abstract 2
- -1 OF 6-AMINO, 4-CARBONYL-PYRIMIDINE Chemical group 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 208000019693 Lung disease Diseases 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical class [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
REFERIDA A UN DERIVADO HETEROCICLICO DE FORMULA (I), DONDE R1 ES H, HALOGENO, CN, O-ALQUILO C1-C4, ENTRE OTROS; R7 ES CICLOALQUILO C3-C8, ARILO C5-C10, HETEROARILO C5-C10, ENTRE OTROS; R2 ES H, HALOGENO, CN, ALQUILO C1-C4, ENTRE OTROS; R3 ES H, METILO, ETILO, PROPILO, ENTRE OTROS; n ES 1, 2 O 3; G Y E SON C-H O N; Z ES C; R4 Y R5 SON H, ALQUILO C1-C6, NH2, ENTRE OTROS; R6 ES H, ALQUILO C1-C4, HALOGENO, CN, ENTRE OTROS. DICHOS COMPUESTOS TIENEN ACTIVIDAD ANTAGONISTA SOBRE EL RECEPTOR 2 DE QUIMIOCINA CC (CCR2) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES TALES COMO ASMA Y EPOC
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179555 | 2009-12-17 | ||
| EP10162621 | 2010-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121614A1 true PE20121614A1 (es) | 2012-12-21 |
Family
ID=43533115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000827A PE20121614A1 (es) | 2009-12-17 | 2010-12-13 | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 |
Country Status (36)
| Country | Link |
|---|---|
| US (6) | US8765949B2 (es) |
| EP (3) | EP2813503B1 (es) |
| JP (1) | JP5632014B2 (es) |
| KR (1) | KR101530234B1 (es) |
| CN (1) | CN102933579B (es) |
| AP (1) | AP3170A (es) |
| AR (1) | AR079636A1 (es) |
| AU (1) | AU2010332969B2 (es) |
| BR (1) | BR112012015873B1 (es) |
| CA (1) | CA2782464C (es) |
| CL (1) | CL2012001311A1 (es) |
| CO (1) | CO6650336A2 (es) |
| CY (1) | CY1115873T1 (es) |
| DK (1) | DK2513093T3 (es) |
| EA (1) | EA024397B1 (es) |
| EC (1) | ECSP12012010A (es) |
| ES (2) | ES2524829T3 (es) |
| GE (1) | GEP20146124B (es) |
| HR (1) | HRP20141143T1 (es) |
| IL (1) | IL219421A (es) |
| MA (1) | MA33818B1 (es) |
| ME (1) | ME01908B (es) |
| MX (2) | MX346393B (es) |
| MY (1) | MY160471A (es) |
| NZ (1) | NZ599770A (es) |
| PE (1) | PE20121614A1 (es) |
| PH (1) | PH12012501215A1 (es) |
| PL (2) | PL2513093T3 (es) |
| PT (2) | PT3091012T (es) |
| RS (1) | RS53555B1 (es) |
| SG (1) | SG181722A1 (es) |
| SI (1) | SI2513093T1 (es) |
| TN (1) | TN2012000300A1 (es) |
| TW (1) | TWI473800B (es) |
| UY (1) | UY33109A (es) |
| WO (1) | WO2011073154A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| KR101754698B1 (ko) | 2008-12-19 | 2017-07-26 | 센트렉시온 테라퓨틱스 코포레이션 | 염증, 천식 및 ｃｏｐｄ 치료용 ｃｃｒ2 수용체 길항제로서의 사이클릭 피리미딘-4-카복스아미드 |
| HRP20141143T1 (hr) | 2009-12-17 | 2015-01-02 | Boehringer Ingelheim International Gmbh | Novi antagonisti receptora ccr2 i njihove uporabe |
| US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| EP2576542B1 (en) | 2010-05-25 | 2015-04-22 | Boehringer Ingelheim International GmbH | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| WO2012171863A1 (en) * | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| US8877185B2 (en) | 2012-05-10 | 2014-11-04 | Stan S. Sastry | Managing and treating keloids |
| WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
| SI3297438T1 (sl) | 2015-05-21 | 2022-03-31 | Chemocentryx, Inc. | CCR2 modulatorji |
| BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
| ES2966111T3 (es) * | 2016-06-03 | 2024-04-18 | Chemocentryx Inc | Pirrolo-piridinas y pirrolo-pirimidinas para su uso en el tratamiento de la fibrosis hepática |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| MX382778B (es) * | 2016-06-13 | 2025-03-13 | Chemocentryx Inc | Metodos para tratar cancer pancreatico |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| IL294410B2 (en) | 2016-11-23 | 2024-02-01 | Chemocentryx Inc | Method of treating focal segmental glomerulosclerosis |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3687525B1 (en) | 2017-09-25 | 2025-10-29 | ChemoCentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN111417389A (zh) | 2017-10-11 | 2020-07-14 | 坎莫森特里克斯公司 | Ccr2拮抗剂对局灶性节段性肾小球硬化症的治疗 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| ES2991280T3 (es) | 2018-01-08 | 2024-12-03 | Chemocentryx Inc | Antagonistas de CCR2 para el tratamiento del linfoma cutáneo de linfocitos T |
| US20210322412A1 (en) * | 2020-04-20 | 2021-10-21 | Centrexion Therapeutics Corporation | Methods and compositions for treating a coronavirus infection |
| NL2026714B1 (en) * | 2020-10-20 | 2022-06-16 | Lumicks Ca Holding B V | Improved detection of lymphocyte - target cell interaction |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US213428A (en) * | 1879-03-18 | Improvement in harrow-teeth | ||
| US568885A (en) * | 1896-10-06 | Can-seaming mechanism | ||
| US4032526A (en) | 1975-10-02 | 1977-06-28 | American Cyanamid Company | 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts |
| GB2068961B (en) | 1980-02-13 | 1983-11-30 | Sankyo Co | Quinazoline derivatives |
| DE3517617A1 (de) | 1985-05-15 | 1986-11-20 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel |
| JPS6319745Y2 (es) | 1985-11-07 | 1988-06-01 | ||
| JPS61165445A (ja) | 1986-01-08 | 1986-07-26 | 株式会社巴組鐵工所 | 振動を減少しうる床構造 |
| US5096916A (en) | 1990-05-07 | 1992-03-17 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline |
| AU678186B2 (en) | 1992-10-23 | 1997-05-22 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
| JP3166376B2 (ja) | 1993-02-03 | 2001-05-14 | 松下電器産業株式会社 | 熱利用装置 |
| US5629235A (en) | 1995-07-05 | 1997-05-13 | Winbond Electronics Corporation | Method for forming damage-free buried contact |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6437138B1 (en) | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| BR9813279B1 (pt) | 1997-10-27 | 2010-11-16 | derivado de homopiperazina, composição farmacêutica, e, uso do derivado de homopiperazina. | |
| CA2350081A1 (en) | 1998-11-20 | 2000-06-02 | G.D. Searle & Co. | Process for making 5-substituted pyrazoles using dithietanes |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| IL145741A0 (en) | 1999-05-04 | 2002-07-25 | Schering Corp | Piperazine derivatives useful as ccrs antagonists |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| US20020045613A1 (en) | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| KR100858642B1 (ko) | 2000-05-22 | 2008-09-17 | 아벤티스 파마슈티칼스 인크. | 트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체 |
| ES2228965T3 (es) | 2000-10-12 | 2005-04-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion y su uso para la produccion de un medicamento. |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| EP1401445B1 (de) | 2001-06-22 | 2006-08-23 | Boehringer Ingelheim Pharma GmbH & Co.KG | Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels |
| US20050143372A1 (en) | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| US6806279B2 (en) | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| CN1628109A (zh) | 2002-02-05 | 2005-06-15 | 诺沃挪第克公司 | 新颖的芳基－与杂芳基－哌嗪 |
| JP2003240776A (ja) | 2002-02-13 | 2003-08-27 | Horiba Ltd | クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置 |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| EA006707B1 (ru) | 2002-03-13 | 2006-02-24 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| CA2483253A1 (en) | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
| NZ536477A (en) | 2002-04-29 | 2005-05-27 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| AU2003237446A1 (en) | 2002-06-05 | 2003-12-22 | Pharmacia Corporation | Pyrazole-derivatives as p38 kinase inhibitors |
| WO2004024710A1 (en) | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| US20040147561A1 (en) | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| WO2004074438A2 (en) * | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| MXPA05009661A (es) | 2003-03-12 | 2006-03-08 | Kudos Pharm Ltd | Derivados de ftalazinona. |
| JP2006528939A (ja) | 2003-04-23 | 2006-12-28 | グラクソ グループ リミテッド | ピペラジン誘導体ならびに神経および精神疾患の治療のためのその使用 |
| FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| ATE370135T1 (de) | 2003-07-18 | 2007-09-15 | Glaxo Group Ltd | Substituierte piperidine als histamin-h3- rezeptorliganden |
| CA2532236C (en) | 2003-07-29 | 2011-08-23 | Novo Nordisk A/S | Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
| JP4740151B2 (ja) | 2003-12-18 | 2011-08-03 | インサイト コーポレイション | ケモカイン受容体のモジュレーターとしての３‐シクロアルキルアミノピロリジン誘導体 |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| JP4845873B2 (ja) | 2004-03-03 | 2011-12-28 | ケモセントリックス インコーポレーティッド | 二環式および架橋した窒素複素環 |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| CA2561791A1 (en) | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| CA2567851A1 (en) | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| RU2389731C2 (ru) | 2004-06-02 | 2010-05-20 | Такеда Фармасьютикал Компани Лимитед | Конденсированное гетероциклическое соединение |
| FR2871157A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Produits biaryl aromatiques, compositions les contenant et utilisation |
| BRPI0512535A (pt) | 2004-06-24 | 2008-03-25 | Incyte Corp | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações |
| BRPI0512623A (pt) | 2004-06-25 | 2008-03-25 | Janssen Phamaceutica N V | sal quaternário antagonista de ccr2 |
| CN1976707A (zh) * | 2004-06-28 | 2007-06-06 | 因赛特公司 | 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类 |
| WO2006004741A2 (en) * | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| AU2005276229A1 (en) | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| MX2007003325A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa. |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| JP5337375B2 (ja) | 2004-11-02 | 2013-11-06 | ノースウェスタン ユニバーシティ | ピリダジン化合物、組成物および方法 |
| PA8653301A1 (es) | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin |
| DE102004061751A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Cyanoguanidin-substituierte Pyrazoline |
| EP2607362B1 (en) | 2005-02-17 | 2014-12-31 | Astellas Pharma Inc. | Piperidine and piperazine carboxylates as FAAH inhibitors |
| EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| CA2604920A1 (en) | 2005-04-15 | 2006-10-26 | Elan Pharmaceuticals, Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
| JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| RU2435769C2 (ru) | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| BRPI0613564A2 (pt) | 2005-07-04 | 2011-01-18 | Novo Nordisk As | compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
| EP1909797A4 (en) | 2005-08-02 | 2013-02-27 | Neurogen Corp | DIPIPERAZINYL KETONE AND RELATED ANALOG |
| GB0517184D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
| TW200800999A (en) * | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| NZ566862A (en) | 2005-09-27 | 2010-12-24 | Irm Llc | Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20100016289A1 (en) | 2005-11-01 | 2010-01-21 | Kevin Sprott | Compounds Useful as Antagonists of CCR2 |
| WO2007092065A2 (en) | 2005-11-14 | 2007-08-16 | Irm Llc | Compounds and compositions as lxr modulators |
| US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| US20090005363A1 (en) | 2005-12-20 | 2009-01-01 | Ralf Glatthar | Organic Compounds |
| IL172838A (en) | 2005-12-27 | 2010-06-16 | Joma Int As | Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby |
| WO2007084868A2 (en) | 2006-01-17 | 2007-07-26 | Kalypsys, Inc. | Treatment of disorders by activation of the unfolded protein response |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007100851A1 (en) | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Therapeutic compounds |
| WO2007105058A2 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| JP2009533435A (ja) | 2006-04-11 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | ジアリール置換アルカン |
| US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| EP2015751A2 (en) | 2006-04-28 | 2009-01-21 | Northwestern University | Salts of pyridazine compounds |
| DE602007004618D1 (de) | 2006-06-22 | 2010-03-18 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren |
| US7935715B2 (en) | 2006-07-28 | 2011-05-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| GB0617575D0 (en) | 2006-09-06 | 2006-10-18 | Syngenta Ltd | Herbicidal compounds and compositions |
| EA200900403A1 (ru) | 2006-09-25 | 2009-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения, которые модулируют рецептор св2 |
| CN101534824A (zh) | 2006-11-17 | 2009-09-16 | 艾博特公司 | 作为化学活素受体拮抗剂的氨基吡咯烷 |
| UA97506C2 (xx) | 2006-12-28 | 2012-02-27 | Эбботт Лаборетриз | Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| FR2915552B1 (fr) | 2007-04-27 | 2009-11-06 | Technip France | Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux. |
| WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| CN101687844B (zh) | 2007-07-02 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr2受体拮抗剂的咪唑衍生物 |
| US7977358B2 (en) | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| WO2009026204A1 (en) | 2007-08-22 | 2009-02-26 | Irm Llc | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| CN101801952A (zh) | 2007-10-01 | 2010-08-11 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物 |
| EP2325180A1 (en) | 2007-10-09 | 2011-05-25 | F. Hoffmann-La Roche AG | Chiral CIS-imidazolines |
| US20100218349A1 (en) | 2007-10-12 | 2010-09-02 | Whang Jong O | Tying tool for shoelace |
| WO2009067406A1 (en) | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| EP2225223B1 (de) * | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
| AU2009259496A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Novel heteroaryl carboxamide derivatives |
| RU2523448C2 (ru) | 2008-08-04 | 2014-07-20 | СиЭйчДиАй ФАУНДЕЙШН, Инк, | Ингибиторы кинуренин-3-монооксигеназы |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| CA2735208A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| KR20110063438A (ko) | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물 |
| KR101754698B1 (ko) | 2008-12-19 | 2017-07-26 | 센트렉시온 테라퓨틱스 코포레이션 | 염증, 천식 및 ｃｏｐｄ 치료용 ｃｃｒ2 수용체 길항제로서의 사이클릭 피리미딘-4-카복스아미드 |
| WO2010094126A1 (en) | 2009-02-23 | 2010-08-26 | Merck Frosst Canada Ltd. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP5658272B2 (ja) * | 2009-12-17 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２の新規アンタゴニスト及びこれらの使用 |
| HRP20141143T1 (hr) | 2009-12-17 | 2015-01-02 | Boehringer Ingelheim International Gmbh | Novi antagonisti receptora ccr2 i njihove uporabe |
| WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| EP2576542B1 (en) | 2010-05-25 | 2015-04-22 | Boehringer Ingelheim International GmbH | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| WO2012171863A1 (en) | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| JP6229575B2 (ja) | 2014-03-31 | 2017-11-15 | 京セラドキュメントソリューションズ株式会社 | 画像処理装置 |
| BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
-
2010
- 2010-12-13 HR HRP20141143AT patent/HRP20141143T1/hr unknown
- 2010-12-13 BR BR112012015873-2A patent/BR112012015873B1/pt not_active IP Right Cessation
- 2010-12-13 WO PCT/EP2010/069549 patent/WO2011073154A1/en not_active Ceased
- 2010-12-13 CA CA2782464A patent/CA2782464C/en active Active
- 2010-12-13 PH PH1/2012/501215A patent/PH12012501215A1/en unknown
- 2010-12-13 AP AP2012006276A patent/AP3170A/xx active
- 2010-12-13 RS RS20140526A patent/RS53555B1/sr unknown
- 2010-12-13 KR KR1020127014412A patent/KR101530234B1/ko active Active
- 2010-12-13 GE GEAP201012789A patent/GEP20146124B/en unknown
- 2010-12-13 ME MEP-2014-106A patent/ME01908B/me unknown
- 2010-12-13 PE PE2012000827A patent/PE20121614A1/es active IP Right Grant
- 2010-12-13 NZ NZ599770A patent/NZ599770A/en not_active IP Right Cessation
- 2010-12-13 EP EP14177921.5A patent/EP2813503B1/en not_active Not-in-force
- 2010-12-13 MX MX2013008863A patent/MX346393B/es unknown
- 2010-12-13 MY MYPI2012002736A patent/MY160471A/en unknown
- 2010-12-13 AU AU2010332969A patent/AU2010332969B2/en active Active
- 2010-12-13 MX MX2012006964A patent/MX2012006964A/es active IP Right Grant
- 2010-12-13 JP JP2012543667A patent/JP5632014B2/ja active Active
- 2010-12-13 PT PT161570270T patent/PT3091012T/pt unknown
- 2010-12-13 PL PL10796336T patent/PL2513093T3/pl unknown
- 2010-12-13 ES ES10796336.5T patent/ES2524829T3/es active Active
- 2010-12-13 EP EP16157027.0A patent/EP3091012B1/en active Active
- 2010-12-13 CN CN201080057415.2A patent/CN102933579B/zh active Active
- 2010-12-13 DK DK10796336.5T patent/DK2513093T3/da active
- 2010-12-13 SG SG2012044129A patent/SG181722A1/en unknown
- 2010-12-13 SI SI201030770T patent/SI2513093T1/sl unknown
- 2010-12-13 EA EA201200876A patent/EA024397B1/ru not_active IP Right Cessation
- 2010-12-13 EP EP10796336.5A patent/EP2513093B1/en active Active
- 2010-12-13 PL PL16157027T patent/PL3091012T3/pl unknown
- 2010-12-13 PT PT107963365T patent/PT2513093E/pt unknown
- 2010-12-13 ES ES16157027.0T patent/ES2674275T3/es active Active
- 2010-12-16 TW TW99144272A patent/TWI473800B/zh not_active IP Right Cessation
- 2010-12-16 AR ARP100104699A patent/AR079636A1/es not_active Application Discontinuation
- 2010-12-16 UY UY33109A patent/UY33109A/es not_active Application Discontinuation
- 2010-12-16 US US12/969,745 patent/US8765949B2/en active Active
-
2012
- 2012-04-25 IL IL219421A patent/IL219421A/en active IP Right Grant
- 2012-05-18 CL CL2012001311A patent/CL2012001311A1/es unknown
- 2012-06-13 TN TNP2012000300A patent/TN2012000300A1/en unknown
- 2012-06-14 MA MA34961A patent/MA33818B1/fr unknown
- 2012-06-15 CO CO12101565A patent/CO6650336A2/es active IP Right Grant
- 2012-06-28 EC ECSP12012010 patent/ECSP12012010A/es unknown
-
2014
- 2014-04-24 US US14/260,552 patent/US9670222B2/en active Active
- 2014-11-12 CY CY20141100939T patent/CY1115873T1/el unknown
-
2017
- 2017-05-26 US US15/606,749 patent/US10196402B2/en active Active
-
2018
- 2018-12-27 US US16/233,315 patent/US11046706B2/en active Active
-
2021
- 2021-06-11 US US17/345,110 patent/US11731981B2/en active Active
-
2023
- 2023-07-31 US US18/362,028 patent/US12209094B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121614A1 (es) | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 | |
| PE20120061A1 (es) | Derivados de pirimidina como antagonistas del receptor ccr2 | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
| PE20130576A1 (es) | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20110153A1 (es) | Derivados de piridazina como inhibidores de smo | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| CR20110620A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20081887A1 (es) | Nuevo compuesto de adenina | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| UY30874A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
| PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
| PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
| CO6260134A2 (es) | Derivados de isoquinolinona como antagonistas nk3 | |
| UY32547A (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |